Werfen

Werfen

Global specialized diagnostics provider

Overview

Werfen focuses on in vitro diagnostics, offering specialized diagnostic solutions for healthcare. It provides tests and instruments for areas like hemostasis (blood clotting), acute care diagnostics, and autoimmunity, used by clinical laboratories to detect and monitor diseases. The company's products combine diagnostic assays, reagents, and instrumentation that run in laboratory workflows to produce actionable patient results. Werfen differentiates itself through its long-standing family-owned heritage, strategic growth including the 1991 acquisition of Instrumentation Laboratory, and a global footprint that spans 30 countries with active presence in more than 100 territories. The goal is to improve patient care by expanding access to accurate, high-quality diagnostic tools and services while maintaining a strong commitment to quality and specialized solutions.

About Werfen

Simplify's Rating
Why Werfen is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Industrial & Manufacturing

Healthcare

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$550M

Headquarters

Barcelona, Spain

Founded

1966

Get referred to Werfen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Werfen reported €2.131 billion sales on April 9, 2026, with 3.3% organic growth.
  • August 19, 2026 IMV ServiceTrak awards validated coagulation customer satisfaction, system performance, and service.
  • Bedford expansion and 2026 hiring keep adding capacity, with headcount above 7,300 worldwide.

What critics are saying

  • PEI notices in February 2026 flagged LIFECODES and Checkcell defects across multiple lots.
  • Repeated product notifications expose quality-control risk that hits trust, recalls, and distributor relationships.
  • Seegene technology sharing and nanopore sequencing commoditize transplant workflows, pressuring Werfen's moat.

What makes Werfen unique

  • Werfen dominates specialized diagnostics in hemostasis, acute care, and transplant testing.
  • Omixon acquisition in 2024 and Oxford Nanopore collaboration in 2026 deepen transplant diagnostics.
  • Bedford's 169,000-square-foot R&D campus anchors Werfen's U.S. innovation engine.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$550M

Above

Industry Average

Funded Over

1 Rounds

Debt funding comparison data is currently unavailable. We're working to provide this information soon!
Debt Funding Comparison
Coming Soon

Benefits

Remote Work Options

Company News

Container News
Sep 4th, 2026
Roberta Duarte to join Maersk as Chief People Officer.

Roberta Duarte to join Maersk as Chief People Officer. September 4, 2026 A.P. Moller - Maersk has appointed Roberta Duarte as its new Chief People Officer. Duarte will also join Maersk's Executive Leadership Team when she assumes the role on 1 November 2026. The appointment marks her return to the Danish shipping and logistics company after a decade with the group. Duarte previously worked at Maersk between 2014 and 2024. During that period, she held senior people leadership positions across Asia Pacific, Latin America and the company's Ocean and Logistics businesses. Duarte subsequently joined medical technology company Werfen, where she currently serves as Chief People Officer. Before beginning her first tenure at Maersk, the Brazilian executive worked at Citibank and held several roles across Latin America and North America.

PR Newswire
Aug 19th, 2026
WERFEN RECEIVES 2026 IMV ServiceTrak(TM) AWARDS FOR BEST CUSTOMER SATISFACTION, SYSTEM PERFORMANCE AND SERVICE IN COAGULATION.

WERFEN RECEIVES 2026 IMV ServiceTrak(TM) AWARDS FOR BEST CUSTOMER SATISFACTION, SYSTEM PERFORMANCE AND SERVICE IN COAGULATION. Aug 19, 2026, 09:37 ET BEDFORD, Mass., Aug. 19, 2026 /PRNewswire/ - Werfen today announced it has received all three 2026 IMV ServiceTrak(TM) Clinical Laboratory Awards in Coagulation (Hemostasis), earning Best Customer Satisfaction, Best System Performance, and Best Service. Based on independent feedback from laboratory professionals nationwide, the awards recognize manufacturers that deliver outstanding customer satisfaction, system reliability, and service excellence. These awards build on Werfen's leadership in the Coagulation category since its introduction in 2018 and underscore the company's long-standing commitment to delivering reliable performance, responsive support, and positive customer outcomes. The IMV ServiceTrak 2026 Clinical Laboratory Awards are based on independent research conducted with clinical laboratory professionals across the United States. Results are based on interviews from nearly 2,000 clinical testing locations representing more than 4,000 instruments. For more than 25 years, the ServiceTrak(TM) program has served as an industry benchmark for customer satisfaction, system performance, and service excellence. "We are honored to receive the 2026 IMV Awards, a recognition that reflects the quality of our products and the exceptional service we provide to our customers," said Bill Crandell, Vice President of North America Commercial Operations at Werfen. "This achievement is a testament to the dedication and specialization of our entire team - from the people who design and manufacture our innovative solutions to those who support our customers every day. Together, this commitment enables us to fulfill our purpose of Powering Patient Care." "Winning the ServiceTrak Best of Customer Satisfaction, Best System Performance and Best Service awards reflects real feedback from the clinical lab professionals who use Werfen's systems every day," said Richa Singh, VP Strategic Insights, at IMV, part of Science and Medicine Group. "These awards are grounded in independent, data-driven research, which makes them one of the most credible benchmarks in the industry." Werfen Receives 2026 IMV ServiceTrak Awards for Best Customer Satisfaction, System Performance and Service in Coagulation About Werfen's Complete Hemostasis Solution Werfen's Complete Hemostasis Solution is comprised of in vitro diagnostics systems, reagents and automation solutions used to diagnose and guide treatment of thrombotic and bleeding disorders. The ACL TOP(R) Family 70 Series provide a standardized family of systems for Hemostasis testing. The comprehensive HemosIL(R) portfolio, including routine and specialty reagents, is designed for general screening and disease-state management. For even greater productivity, HemoCell(R) Specialized Lab Automation, customized for each lab, optimizes testing workflow via specialized automation. HemoHub(R) Intelligent Data Manager provides central management of Werfen Hemostasis systems. And Werfen's award-winning* Service and Support teams partner with customers to ensure optimal instrument operation, and provide training and 24/7 Technical Support. About IMV Each year, IMV, a part of Science and Medicine Group, produces a series of proprietary ServiceTrak reports derived from research conducted directly with clinical lab professionals across the United States. The ServiceTrak Program represents an independent analysis of service trends in multiple laboratory diagnostic modalities and includes manufacturer ratings for 38 attributes to determine what drives probability of repurchase and customer satisfaction. As part of the ServiceTrak Program, awards are given to the top provider in each modality across three categories: Best of Customer Satisfaction, Best of System Performance, and Best of Service. Based on interviews from nearly 2,000 clinical testing locations and over 4,000 instruments, ServiceTrak has been the industry benchmark for over 25 years. About Werfen Werfen (www.werfen.com), founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company's clinical areas of focus include Hemostasis, Acute Care, Transfusion, Autoimmunity, and Transplant. The Hemostasis portfolio includes ACL TOP Family 70 Series, ACL TOP Family 50 Series, ACL Elite(R) Pro and ACL AcuStar(R), HemoCell Specialized Lab Automation, HemoHub Intelligent Data Manager, along with the comprehensive line of HemosIL reagents. *Recipient of the 2026 IMV ServiceTrak(TM) Best Service Award in Coagulation SOURCE Werfen

Manufacturing & Logistics Online
May 29th, 2026
Werfen and Oxford Nanopore collaborate to enhance transplant testing.

Werfen and Oxford Nanopore collaborate to enhance transplant testing. Werfen and Oxford Nanopore Technologies have expanded their collaboration to validate Werfen's transplant assays on Oxford Nanopore's sequencing platforms, aiming to deliver faster, more accurate donor-recipient matching. May 29, 2026 Werfen announced a strategic collaboration with Oxford Nanopore Technologies to validate Werfen's specialized transplant assay portfolios for use on Oxford Nanopore's sequencing platforms. Building on a collaboration between Werfen and Oxford Nanopore that began in 2020, this marks a significant milestone, combining Werfen's validated, high-precision transplant assays with Oxford Nanopore's rapid, information-rich sequencing technology. Together, the companies aim to streamline laboratory workflows, providing a fast and accurate "DNA-to-result" experience that leverages the speed and scalability of nanopore sequencing. By ensuring the optimization and compatibility of Werfen's transplant portfolio, including solutions for Human Leukocyte Antigen (HLA) typing and pre-transplant matching, with Oxford Nanopore's platforms, the aim is to enable laboratories to implement high-quality testing with reduced complexity and faster results. This is particularly critical in transplantation, where rapid, high-resolution data is essential for donor-recipient matching and long-term success.

TradingView
Mar 10th, 2026
AcouSort receives prepayment of royalties

AcouSort receives prepayment of royalties. AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum royalties for 2027 and 2028. Together with Werfen's regular 2026 minimum royalty, the total sum payable to AcouSort in early 2026 amounts to approximately USD 1.3 million. "Based on our current cash position and this prepayment together with Werfen's regular 2026 minimum royalties alone will fund AcouSort into 2027," said AcouSort's CEO Dr. Torsten Freltoft. The original agreement was signed in spring 2018. Using AcouSort acoustofluidic background technology, the parties jointly developed the solution now implemented in Werfen's groundbreaking GEM Premier 7000 system for point-of-care blood gas analysis. The hemolysis detection in GEM Premier 7000 is based upon patented acoustofluidic technology for plasma separation, combined with photometric determination. In just 45 seconds, the GEM Premier 7000 detects hemolysis, while delivering a complete menu of blood-gas results (pH, pO2, pO2, sodium, potassium, ionized calcium, chloride, glucose, lactate, hematocrit, total hemoglobin, total bilirubin and CO-Oximetry). No other terms of the License and Distribution Agreement with Werfen have been changed. In terms of liquidity, the change takes effect within Q1, while revenue recognition occurs according to applicable accounting principles. This information is information that AcouSort is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-03-10 17:30 CET. FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT: Torsten Freltoft, CEO Telephone: +45 2045 0854 E-mail:[email protected] ABOUT ACOUSORT AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing - so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB. Attachments AcouSort receives prepayment of royalties

BioTecNika Global
Jan 5th, 2026
Biological Sciences Manufacturing Job at Werfen North America | Apply now

Biological sciences manufacturing job at Werfen North America | Apply now. Manufacturing Associate role at Werfen North America. Werfen North America is hiring for a Manufacturing Associate 1 position in San Diego, CA. This manufacturing job offers an opportunity to work in a regulated life sciences environment, supporting the production of advanced autoimmune diagnostic products used by clinicians worldwide. The Manufacturing Associate role is ideal for candidates seeking hands-on experience in diagnostic kit manufacturing while working with automated equipment and quality-driven processes. Job details: * Job Title: Manufacturing Associate 1 * Location: San Diego, California * Industry: Life Sciences / Diagnostics Manufacturing * Employment Type: Full-time * Department: Autoimmunity Manufacturing * Salary Range: $25/hr to $30/hr * Team: QUANTA Flash and Aptiva Manufacturing Team About Werfen North America: Werfen North America is a global leader in specialized diagnostics, focusing on autoimmune, hemostasis, acute care, and transfusion medicine. The company is committed to delivering high-quality diagnostic solutions that help healthcare professionals improve patient outcomes. Werfen North America operates under strict quality systems and regulatory standards, ensuring innovation, safety, and reliability across all manufacturing processes. Apply for more similar Manufacturing job offers in the USA. Educational requirements: * Bachelor's degree in biological or related sciences is required * Certificate program or Associate's degree with 3 - 4 years of relevant life sciences laboratory experience may be substituted * Relevant work experience may be considered in place of formal education at management's discretion Key responsibilities for Manufacturing Associate role: * Follow standard operating procedures and work instructions under supervision * Manufacture and test in-process components and diagnostic reagents * Participate in bulking and evaluation of reagents and components * Operate, clean, and maintain manufacturing equipment and instrumentation * Package and fill components according to manufacturing procedures * Maintain accurate Device History Records and related documentation * Assist with evaluation of raw materials when required * Ensure compliance with ISO, FDA, and Quality Management System regulations * Maintain a clean, safe, and organized lab and work environment * Reflect Werfen values in daily work and team interactions Skills required for Manufacturing Associate role: * Basic knowledge of laboratory practices and procedures * Understanding of Good Manufacturing Practices (GMP) * Strong attention to detail and quality standards * Ability to identify product defects or equipment issues * Problem-solving and troubleshooting skills * Effective time management skills * Ability to work collaboratively in a team environment * Willingness to learn and adapt in a regulated manufacturing setting Benefits of the Manufacturing Associate role: * Competitive hourly pay ranging from $25 to $30 per hour * Medical, dental, and vision insurance coverage * 401(k) retirement plan with employer match * Paid vacation and sick leave * Opportunity to work in a highly specialized diagnostic manufacturing environment * Career growth opportunities within Werfen North America

Recently Posted Jobs

Sign up to get curated job recommendations

Werfen is Hiring for 109 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →